Clinical Trial Regulation and EMA Policy 0070 restart

EMA policy 0070 Relaunch in September 2023 – What you should need to know! 

EMA Policy 0070 is to be relaunched in September 2023. This was announced by the European Medicines Agency during a webinar held on May 16, 2023. 

All Marketing Authorization Holders who submit packages to EMA should immediately implement document anonymization processes. 

EMA Policy 0070, which was originally implemented on January 1, 2015, has been around for almost a decade. The suspension of EMA Policy 0070 in December 2018 was due to the COVID Pandemic. But now, EMA Policy 0070 will be reactivated. 

What is the scope of this document?

Sponsors should be aware that EMA Policy 0070 has remained largely unchanged, but some changes have been made to the procedures. 

The scope of relaunch includes 

  • New Active Substances (NAS), September 2023   
  • Negative and withdrawn goods   
  • COVID-19 (and other Public Health Emergency Clinical Data)   
  • MAHs affected will receive detailed, specific letters inviting them to request the packages   
  • Meetings to discuss the scope of publication, anonymization strategy, and commercially sensitive information CCI strategy.   

Changes to improve efficiency and continue collaboration with Health Canada.

What’s new in EMA Policy 0070 relaunch? 

The EMA Policy 0070 Team will work closely with the Clinical Trial Information System team (CTIS) to ensure that both efforts are uniform and consistent. The EMA wants to complete package preparation as soon as possible – as soon as the sponsors receive a letter of invitation from EMA in relation to EMA Policy 0070. 

Pre-submission meetings will be tailored to each product. The scope of publication as well as anonymization will be discussed at this meeting. 

The EMA will develop new templates for anonymization reports in collaboration with Health Canada. It will also draft a list for the marketing authorization holder of the documents that are eligible for anonymization. 

Re-launching EMA Policy 0070 enhances transparency and public trust in clinical research by allowing researchers and healthcare professionals access to clinical data. This policy will enhance the scientific integrity and safety of healthcare decisions by ensuring efficient and safe clinical trials. 

Key Points from Webinar 

  • Any submission getting decision from September 2023 would be eligible to submit the anonymized package as per Policy 0070. 
  • Submission done after suspension of Policy 0070 after Brexit and before September 2023 would not need to be published immediately but it would be done based on request and proper planning to avoid burden on Sponsors and EMA. 
  • Invitation letters will be sent if your product is in scope. 
  • Emphasis on 1) early preparation of packages for submission – prior to Opinion and 2) Complete QC check prior to submission – all documents present. 
  • EMA worked collaboratively with Health Canada to create a common template for anonymization report. 
  • EMA Policy 0070 Team will work closely with the Clinical Trial Information System team (CTIS) to ensure that both efforts are uniform and consistent. However, anything redacted as CCI for CTIS does not make it eligible for CCI for Policy 0070. Following were the major reasons of rejection of CCI and shall be considered for future: 
  • Information is already in public domain. 
  • Specific details shall be redacted as CCI in place of complete paragraphs. 
  • Lack of Proper justification for CCI to explain how it impacts economic benefit of the sponsor. 
  • Covid-19 projects are still of interest to the public and will continue to be published under Policy 0070 even if a decision on it is made before September 2023. 
  • Timelines have been revised from 60 days to 120 days for publishing the anonymized package from the date of CHMP opinion on initial marketing authorization applications. 

Important Links:



[4] Clinical Data Publication (Policy 0070) re-launch – EMA webinar | European Medicines Agency (

By Parveen KumarHead of Data Transparency & Product Owner, GENINVO

For questions on this article, please contact us.

More Blogs

The Importance of Automation in Clinical Trials 

Introduction  Clinical trials are the backbone of medical research and innovation. They play a pivotal role in advancing healthcare, developing…
Read More

Quick Look at Software Testing

Introduction Software testing plays a vital part of the software development lifecycle that ensures the quality, reliability, and performance of…
Read More

Ensuring GDPR Compliance with Advanced Data Anonymization Solutions

Introduction In an increasingly interconnected world, where every digital interaction leaves a trace, safeguarding personal data has become a paramount…
Read More

Managing Product Development Amidst Regulatory Changes Landscape 

Introduction  In today’s fast-paced business environment, product development is a critical aspect of staying competitive and meeting consumer demands. However,…
Read More

Overview of Clinical Data Sharing and Data Anonymization

Need for Data Sharing For biomedical research, Clinical trials are essential components as they lay down the foundation for the…
Read More

Synthetic Patient Data in Clinical Trials: Why it’s important to have meaningful synthetic data. 

It is time consuming and difficult to manually generate the test data to support Clinical Programming (CP)/Biostatistics and statistical processes…
Read More

EMA policy 0070 Relaunch in September 2023 – What you should need to know! 

EMA Policy 0070 is to be relaunched in September 2023. This was announced by the European Medicines Agency during a…
Read More

Automation within Medical Writing

What does medical writing function do? Medical writing is a highly specialized field that involves content writing and clinical research…
Read More

Synthetic Data Vs Real Data 

There has been an increase in interest in synthetic data over the past few years for various applications such as…
Read More

Data Protection 

The impact of globalization on privacy of identity is growing. The fact that more and more Data Protection, comprising data…
Read More

ISMS Implementation 

Every technology-driven business process is exposed to security and privacy threats. Modern technologies are capable of preventing cybersecurity attacks, but these aren’t enough,…
Read More

What is Password Protection?

Damanjeet Singh – Technical Lead- IT & Infrastructure Passwords provide the first line of defense against unauthorized access to your…
Read More

What is KUBERNETES (k8s)? 

Manish Anupam – Manager-IT & Database In this digital era, every project needs to be built in less time with…
Read More


Gurjeet Dhaunsi – Analyst- QA/CSV ISO (International Organization of Standardization) is non-profit organization which is setup with a goal to…
Read More

Innovation in Medical Writing

Innovation’ denotes new, better, more effective ways of solving problems. An innovation must be something truly new or at least…
Read More

Project Management to support GENINVO Innovation efforts

Given the growth of the pharmaceutical segment, the industry needs to become increasingly better at managing pharmaceutical projects for more…
Read More

Regulatory Bodies in Life Sciences

Regulatory bodies (or regulatory agencies) in Life Sciences as we have come to know them have been around since the…
Read More

Contact Us​

Skip to content